Helping Life-Science companies expand,
partner and execute across Central & Eastern Europe
CEE-FOCUSED | PHARMA, BIOTECH & ONE HEALTH | MARKET ACCESS, LICENSING & SCIENTIFIC BD
We combine scientific credibility with hands-on commercial execution – connecting life-science companies with the right CEE partners, assets, and opportunities.
Market Access &
Representation
Enter new markets with the right partners and regulatory path
How We Help Life-Science Companies
Three core ways we support your growth
Business Development &
Consulting
Identify, structure and execute high-value partnerships
We assess both the scientific credibility and the commercial potential of your asset simultaneously – giving you one integrated view that investors, partners, and acquirers trust.
Scientific Asset Evaluation & BD
We evaluate the science and structure the deal – from licensing strategy to partner identification and negotiation
Manufacturing & CMO
Optimization
Improve efficiency, reduce risk and scale production
Investment Scouting & Due Diligence
CEE health-science deal sourcing and scientific evaluation for investors and funds who lack regional capability
Scientific-Commercial Validation
Manufacturing & CMO
Optimization
Improve efficiency, reduce risk and scale production
Who We Partner With
Pharma
Companies
Biotech & MedTech Startups
We work with a focused set of partners where we can add real, measurable value
Manufacturers /
CDMOs
Pharma
Companies
Biotech &
MedTech Startups
Manufacturers /
CDMOs
Investors &
Asset Owners
Investors &Asset Owners
Scientific-Commercial Partnership Development
Scientific-Commercial Validation
Investment Scouting for Funds
Collaboration Opportunities
Asset Evaluation & Licensing Strategy
We engage in the model that fits your objective – not a one-size approach
Market Entry to CEE
Launch and scale your presence in the region
Product Licensing
& Deals
Connect assets with the right regional partners
Strategic BD
Supply Chain
Our Collaboration
Process
1
Initial Call
Understand your goals
and scope
2
Opportunity
Analysis
Evaluate potential
and define approach
3
Project
Identification
Source and validate
the right project scope
1
Initial Call
Understand your goals
and scope
2
Opportunity
Analysis
Evaluate potential
and define approach
4
3
Partner
Identification
Source and validate
the right partners
Deal Execution
Structure and close
the collaboration
4
Deal Execution
Structure and close
Active Pipeline
Healthcare Product Portfolio |
Where we are active:
Active mandates where we provide scientific validation and commercial deal execution simultaneously – market access, licensing strategy, and partner identification across CEE.
Scientific due diligence and commercial evaluation for investors seeking CEE health-science deal flow – and selected own ventures we are actively co-building with equity stakes.
Pharma, Biotech, One Health, and CBRN assets available for licensing, distribution, or co-development across EU markets.
Scientific BD & Licensing Mandates
Investment Scouting & Venture Building
Orphan Drug Licensing |
Partnering with innovative therapies entering CEE markets
MedTech Partnership |
Supporting expansion of next-gen animal health solutions
Veterinary Innovation |
Supporting expansion of next-gen animal health solutions
Scientific Expertise
Deep expertise you can actually act on
Why PharmNovaTechBridge?
Focused on CEE Region
Deep expertise you can actually act on
Not just advisory.
A partner that delivers.
Scientific Expertise
Deep expertise you can actually act on
Extensive Network
Strong network that opens real doors
Proven Track Record
Proven track record with measurable outcomes
Extensive Network
Strong network that opens real doors
Focused on CEE Region
Local CEE insight that reduces risk